Evidence map›Paper›PMID 28805669›Full record

Trial reportNutrients2017

Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study.

Ludovico Abenavoli, Marta Greco, Natasa Milic, Francesca Accattato, Daniela Foti, Elio Gulletta, Francesco Luzza

2 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 79 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 13 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05605158 phase3unknown statusnot on this mapstarted 2022, after this paper: background citation

Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis

TypeinterventionalSponsorTanta UniversityRan2022 to 2024Enrolled56ConditionsNon Alcoholic SteatohepatitisArmsPioglitazone 30mg, Empagliflozin 10 MG
NCT06321211 completednot on this mapstarted 2024, after this paper: background citation

Development of a Novel Asian Mediterranean Diet and Its Acceptability in Non- Alcoholic Fatty Liver Disease (NAFLD)- a Pre-intervention Study

TypeobservationalSponsorSingapore Institute of TechnologyRan2024 to 2025Enrolled30ConditionsFatty Liver, Nonalcoholic
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 13 syntheses or guidelines pooled it, 136 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Vitamin E for people with non-alcoholic fatty liver disease.The Cochrane database of systematic reviews · 2024
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ludovico AbenavoliDepartment of Health Sciences, University "Magna Græcia", 88100 Catanzaro, Italy. l.abenavoli@unicz.it.
Marta GrecoDepartment of Health Sciences, University "Magna Græcia", 88100 Catanzaro, Italy. marta.greco@unicz.it.
Natasa MilicDepartment of Pharmacy, University of Novi Sad, 21000 Novi Sad, Serbia. milnat@libero.it.
Francesca AccattatoDepartment of Health Sciences, University "Magna Græcia", 88100 Catanzaro, Italy. francescaaccattato@libero.it.
Daniela FotiDepartment of Health Sciences, University "Magna Græcia", 88100 Catanzaro, Italy. foti@unicz.it.
Elio GullettaDepartment of Health Sciences, University "Magna Græcia", 88100 Catanzaro, Italy. gulletta@unicz.it.
Francesco LuzzaDepartment of Health Sciences, University "Magna Græcia", 88100 Catanzaro, Italy. luzza@unicz.it.
Magna Graecia University · ITUniversity of Novi Sad · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, characterized by liver fatty acid accumulation and fibrosis, not due to excessive alcohol consumption. Notably, nutritional habits have been reported to be implicated in the onset and severity of the hepatic damage, while the Mediterranean diet has shown beneficial effects on NAFLD. Free radicals and oxidative stress were suggested to be involved in the pathogenesis and progression of NAFLD, and several data highlighted the efficacy of antioxidant supplementation in its treatment. The aim of this study was to compare the effects of the Mediterranean diet, with or without an antioxidant complex supplement, in overweight patients suffering from NAFLD. In this prospective study, fifty Caucasian overweight patients were randomized into three groups (Groups A-C). A personalized moderately hypocaloric Mediterranean diet was prescribed to all patients included in the A and B groups. In addition to the diet, Group B was administered antioxidant supplementation daily and for the period of six months. Group C did not have any type of treatment. The study proved that the Mediterranean diet alone or in association with the antioxidant complex improved anthropometric parameters, lipid profile and reduced hepatic fat accumulation and liver stiffness. However, Group B patients, in which the diet was associated with antioxidant intake, showed not only a significant improvement in insulin sensitivity, but also a more consistent reduction of anthropometric parameters when compared with Group A patients. Taken together, these results support the benefit of antioxidant supplementation in overweight patients with NAFLD.

Indexed as

Diet, MediterraneanAdultAntioxidantsDietary SupplementsFemaleHumansMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseOverweightProspective StudiesAntioxidantsantioxidantinsulin resistanceMediterranean dietnon-alcoholic fatty liver diseaseweight

Identifiers

PMID28805669
PMCPMC5579663
OpenAlexW2749310292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.